1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,077 | 0,192 | 09:32 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Probiotix Health gross profit and margin jump as sales increase 36% | 2 | Alliance News | ||
| Mo | Probiotix Health PLC - Q3 2026 Trading Update | 1 | RNS | ||
| PROBIOTIX HEALTH Aktie jetzt für 0€ handeln | |||||
| 05.10. | Probiotix Health PLC - Change of Auditor | - | RNS | ||
| 07.08. | EARNINGS AND TRADING: Probiotix flips to profit, eyes "further growth" | 1 | Alliance News | ||
| 06.08. | Probiotix Health PLC - Unaudited Interim Results to 30 June 2026 | 1 | RNS | ||
| 23.07. | Probiotix Health PLC - New Partnership Agreement in Belgium | 1 | RNS | ||
| 23.06. | Probiotix Health PLC - Result of AGM | 1 | RNS | ||
| 01.06. | Probiotix Health PLC - New Partnership Agreement in Slovakia | 1 | RNS | ||
| 29.05. | Probiotix Health PLC - Notice of AGM | 1 | RNS | ||
| 26.05. | TRADING UPDATES: Pathos deal win; ProBiotix eyes "market opportunity" | 3 | Alliance News | ||
| 26.05. | Probiotix Health PLC - New Strategic Alliance in Spain and Portugal | 1 | RNS |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MUSTGROW BIOLOGICS | 0,204 | 0,00 % | Danaher, MustGrow Biologics, Veralto - Milliardenmarkt für grüne Technologien | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics. Die nächste industrielle Revolution findet nicht nur in Rechenzentren und Chipfabriken statt. Auch in Laboren, auf landwirtschaftlichen... ► Artikel lesen | |
| OPTIBIOTIX HEALTH | 0,065 | 0,00 % | WINNERS & LOSERS: Alkemy Capital gets grant; OptiBiotix loss widens | ||
| QIAGEN | 42,820 | 0,00 % | Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur | DJ Finanzinvestor EQT will Qiagen für über 9 Milliarden Euro kaufen - Agentur
DOW JONES--Der Finanzinvestor EQT will einem Agenturbericht zufolge den Diagnostikspezialisten Qiagen übernehmen. Wie... ► Artikel lesen | |
| DISC MEDICINE | 75,94 | -0,08 % | Jefferies raises Disc Medicine stock price target on drug opportunity | ||
| ENLIVEN THERAPEUTICS | 41,820 | 0,00 % | H.C. Wainwright hebt Kursziel für Enliven Therapeutics auf 73 $ an | ||
| CG ONCOLOGY | 62,24 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TANGO THERAPEUTICS | 26,990 | +0,04 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| PRAXIS PRECISION MEDICINES | 256,86 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 24,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| ABSCI | 10,040 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen | |
| NURIX THERAPEUTICS | 26,000 | -0,08 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| SUMMIT THERAPEUTICS | 15,825 | -0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 19,120 | 0,00 % | ArriVent BioPharma, Inc. - 8-K, Current Report | ||
| RAPPORT THERAPEUTICS | 25,060 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins | ||
| ARCUS BIOSCIENCES | 19,080 | -0,03 % | Arcus Biosciences prices $250 million stock offering at $17.50 |
Das Unternehmen PROBIOTIX HEALTH PLC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,015 (+18,95 %) liegt der Kurs bei 0,091 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROBIOTIX HEALTH PLC finden Sie auf Wallstreet Online.